T he most important cause of mortality in patients with chronic renal failure, including dialysis patients, is cardiovascular disease (CVD). The frequency of CVD in dialysis patients has been reported as high as 3 -45 times that observed in the general populations and approximately 50% of deaths in these patients are related to CVD (1, 2) . In peritoneal dialysis (PD) patients, one of the major risk factors for CVD is lipid abnormalities, including low serum concentrations of high density lipoprotein-cholesterol (HDL-C) and apoprotein (apo AI), and high serum concentrations of triglycerides, total cholesterol, low density lipoprotein-cholesterol (LDL-C), apoprotein B100 (apo B100), and particularly lipoprotein(a) [Lp(a)] (3-10). Serum Lp(a) concentration higher than 30 mg/dL, a prevalent lipid abnormality in PD patients, is an important risk factor for CVD (3, 5, (9) (10) (11) (12) (13) (14) (15) . At the present time, blood lipid normalizing drugs such as statins, nicotinic acid, fibric acid derivatives, etc. are used to treat lipid abnormalities and prevent CVD in PD patients; however, no effective treatment to reduce Lp(a) in these patients is known so far (3) .
Some studies, conducted mainly in nonuremic patients, indicate that soy consumption reduces serum concentrations of total cholesterol, LDL-C, triglycerides, and apo B100 and raises serum HDL-C concentration, particularly in hyperlipidemic patients (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) . In addition, limited studies have been conducted to assess the effect of This single copy is for your personal, non-commercial use only. For permission to reprint multiple copies or to order presentation-ready copies for distribution, contact Multimed Inc. at marketing@multi-med.com asked to continue their usual diet and to avoid consuming soy-containing products during the study. Subjects were advised not to change their dietary habits, physical activities, or drug regimens. All CAPD patients were usually dialyzed with four 2-L exchanges of 1.5% and/ or 2.5% glucose-containing dialysis solutions, except for 1 patient who used 4.25% glucose-containing dialysis solutions. At baseline and the end of week 8, 5 mL of blood was obtained from each patient after a 12-to 14-hour fast. Blood samples were centrifuged at 2500 rpm for 15 minutes to separate sera. Serum concentrations of triglycerides, total cholesterol, LDL-C, and HDL-C were measured enzymatically using commercial kits (Pars Azemoon, Tehran, Iran) with the aid of a Hitachi 717 automated analyzer (Boehringer Mannheim Diagnostics, Mannheim, Germany). Serum concentrations of apo B100, apo AI, and Lp(a) were determined by immunoturbidimetric methods using commercial kits (Roche Diagnostics, Mannheim, Germany) with the aid of a Cobas Mira automated analyzer (Roche Diagnostics). Serum albumin concentration was measured by the bromcresol green method using commercial kits (Pars Azemoon) with the aid of a Hitachi 717 automated analyzer. The coefficient of variation for serum lipids, apoproteins, and albumin was less than 3%. Serum tumor necrosis factor-alpha (TNF-α) concentration was determined with the use of enzyme-linked immunosorbent assay (ELISA) kits (Bender MedSystems, Vienna, Austria). The coefficient of variation for serum TNF-α was 6%.
Patients were weighed at baseline and at the end of week 8. In addition, because dietary confounding factors could affect blood lipids and apoproteins, it was necessary to compare the two groups regarding these factors during the study. Therefore, dietary intakes of subjects were assessed using a 24-hour dietary recall for 3 consecutive days at baseline and at the end of weeks 4 and 8. Patients' diets were analyzed by Food Processor II software (ESHA Research, Salem, OR, USA). To ascertain patients' compliance, we provided each patient with a fixed number of soy packets and instructions to return the unconsumed packets at the end of the study. The degree of compliance for each patient was determined according to the number of returned packets and the data of the patients with compliance less than 90% were not analyzed.
STATISTICAL METHODS
Statistical analysis was performed using the Statistical Package for the Social Sciences (SPSS, Inc., Chicago, IL, USA) version 12.0. Chi-square test was used to comsoy consumption in lowering serum Lp(a) concentration (18) (19) (20) 22, 27, 28) , and the majority of these studies, which were randomized controlled trials (18, 20, 22, 27) , have shown that soy protein does not significantly reduce serum Lp(a) (18) (19) (20) 22, 27) . These studies were conducted mainly in nonrenal failure individuals with normal serum level of Lp(a). However, Meinertz et al. showed in a randomized controlled trial that alcohol-extracted soy protein in normolipidemic non renal failure individuals markedly lowered serum Lp(a), especially in individuals with serum Lp(a) level higher than 30 mg/dL (28) . According to the available literature, no such study in this field has been done yet in PD patients. Therefore, the present study was designed to investigate the effects of soy consumption on serum lipids and apoproteins, especially Lp(a), in PD patients.
METHODS
This study was a non-blinded randomized clinical trial. The minimum sample size estimated for each group was 20 at a power (1 -β) of 90% and α = 0.05 for a two-arm parallel study with two-tailed testing to detect a difference of 41 mg/dL in serum Lp(a) concentration, with a pooled standard deviation of 40.1 mg/dL -obtained from Tonstad et al.'s study (18) . Forty patients (20 men, 20 women) undergoing continuous ambulatory PD (CAPD) in the age range of 18 -83 years (mean ± SD: 52 ± 15 years) were recruited from the PD units of Modares Hospital and Shafa Clinic in Tehran, Iran. Patients enrolled in this study did not have thyroid disorders or hyperphosphatemia (serum phosphorus >5.5 mg/dL). In addition, all patients were asked about soy consumption at baseline and subjects that had regularly used soy in their diets within 3 months before the start of the study were excluded. The study protocol was approved by the Ethics Committee of the National Nutrition and Food Technology Research Institute of Iran. Written informed consent was obtained from all patients before initiating the study.
Patients were randomly allocated to either the soy or the control group using a block randomization. Since the study period in the majority of investigations of the effects of soy consumption on blood lipids and apoproteins was between 4 and 12 weeks, mainly 6 weeks, 8 weeks was therefore chosen as the study period. Subjects in the soy group received 28-g packets of raw textured soy flour (containing 14 g of soy protein and 61 mg of isoflavonoids, including genistein, daidzein, and glycitein) and were asked to cook and consume one soy packet instead of one serving of meat (i.e., 60 g of meat) at dinner for 8 weeks. 
RESULTS
Of the 40 CAPD patients initially enrolled, 2 subjects in the soy group were withdrawn because of noncompliance and 2 patients in the control group due to lack of cooperation.
The baseline characteristics of patients did not differ significantly between the two groups ( Table 1 ). In addition, body mass index did not significantly change within each group during the study.
There were no significant differences in mean dietary intake of total energy, protein, carbohydrate, total fat, saturated fatty acids, monounsaturated fatty acids, polyunsaturated fatty acids, or cholesterol between the two groups at baseline or at the end of weeks 4 and 8. In addition, these factors did not significantly change within each group during the study ( Table 2 ).
There were no significant differences between the two groups for dietary intake of vegetable or animal protein at baseline. Mean dietary intake of vegetable protein was significantly higher in the soy group at the end of weeks 4 and 8 compared to the control group (p < 0.01), whereas mean dietary intake of animal protein in the soy group was significantly lower (p < 0.05; Table 2 ). There were no significant differences between the two groups in terms of dietary intake of fiber at baseline or at the end of week 4, but mean dietary intake of fiber was significantly higher in the soy group at the end of week 8 compared to the control group (p < 0.01; Table 2 ). At baseline, 86% of patients had serum Lp(a) higher than 30 mg/dL and there was no significant difference between the two groups in serum Lp(a) concentration. At the end of week 8, serum Lp(a) concentration decreased significantly in the soy group compared to baseline (p < 0.01), whereas no significant change was observed in the control group. The reduction in serum Lp(a) concentration in the soy group was significant compared with the control group (p < 0.05; Table 3 ). Patterns of change in individual serum Lp(a) concentrations during the study in the soy and the control groups are shown in Figures 1 and 2 .
No significant changes were observed in serum concentrations of triglyceride, total cholesterol, HDL-C, LDL-C, or apo B100 within each group during the study (Table 3) . Serum apo AI concentration was decreased significantly in the soy (p < 0.05) and control (p < 0.01) groups at the end of week 8 compared to baseline but serum apo AI reduction was not significantly different between the two groups (Table 3) .
Serum concentration of TNF-α did not significantly change within each group during the study (Table 3) . Serum albumin was increased significantly in the two groups at the end of week 8 compared to baseline (p < 0.01); however, the increase in serum albumin was not significantly different between the two groups (Table 3) .
DISCUSSION
High serum Lp(a) concentration is a common lipid disorder in PD patients (3, 5, 14, 15) and serum Lp(a) concentration higher than 30 mg/dL constitutes a major risk factor for CVD (9) (10) (11) (12) (13) (14) .
At baseline, approximately 86% of all the patients in both groups had serum Lp(a) concentration higher than 30 mg/dL. During the 8 weeks, mean serum Lp(a) decreased significantly, by 41%, in the soy group: from 78 mg/dL at baseline to 46 mg/dL at the end of the study. The reduction was significant compared with the control group. In addition, at baseline, approximately 94.5% of the patients in the soy group had serum Lp(a) higher than 30 mg/dL, but at the end of the study, 72.5% of the patients in the soy group had serum Lp(a) higher than 30 mg/dL. In 83% of the patients in the soy group, serum Lp(a) concentration was decreased at the end of the study compared with baseline.
So far, limited studies have been conducted to assess the effect of soy in lowering serum concentration of Lp(a); the majority of these studies showed soy protein did not reduce serum Lp(a) significantly (18) (19) (20) 22, 27) . These studies were conducted mainly in non renal failure individuals with normal serum level of Lp(a); so we may not expect soy protein to reduce serum level of Lp(a) significantly. However, Meinertz et al. showed that alcohol-extracted soy protein in normolipidemic non renal failure individuals markedly lowered serum Lp(a), especially in individuals with serum Lp(a) level higher than 30 mg/dL (28) . This result is in agreement with our study. Our study is the first investigation on the effect of soy consumption on serum Lp(a) in PD patients, approximately 86% of whom had serum Lp(a) level higher than 30 mg/dL. High serum levels of Lp(a) in PD patients may be due to increased hepatic synthesis of Lp(a) following loss of amino acids and proteins through PD. Some studies have indicated that increased urinary excretion of protein results in increased hepatic synthesis of Lp(a) (5, 15, (29) (30) (31) . In addition, there is an inverse relationship between Lp(a) level and serum albumin (32, 33) . On the other hand, increased hepatic synthesis of Lp(a), which is an acute-phase protein, may be due to increased production of cytokines in dialysis patients (29, 34) .
In the present study, serum concentration of albumin increased significantly in both the soy and the control group but no significant difference was observed between the two groups in the level of serum albumin at baseline or at the end of the study (week 8). Therefore, the reduced concentration of Lp(a) in the soy group cannot be attributed to a rise in serum albumin level because this rise occurred in the control group as well.
Cytokines such as TNF-α stimulate hepatic synthesis of Lp(a) in dialysis patients (29) . In our study, soy consumption for 8 weeks had no significant effect on serum concentration of TNF-α. Therefore, the reduced concentration of Lp(a) in the soy group cannot be attributed to a change in serum TNF-α concentration. In contrast to our study, Huang et al. showed that consuming soy milk for 10 weeks significantly reduced TNF-α level in menopausal women (35) . This disparity may involve the fact that Huang et al.'s research lacked a control group and was conducted in nondialysis subjects.
The textured soy flour was composed substantially of protein, fiber, isoflavonoids, including phytoestrogens, and some carbohydrates. Therefore, the effect of the textured soy flour on serum Lp(a) is related to these components. In the present study, the effect of soy consumption on serum Lp(a) concentration may be because of the direct effect of soy phytoestrogens on Lp(a) synthesis; some studies have indicated that estrogen may reduce serum Lp(a) by 30% (22, 34) through affecting the synthesis of Lp(a) (22) . Thus, soy phytoestrogens may play a role similar to that of estrogen in reducing the synthesis of Lp(a). In addition, some studies have shown that soy protein (without isoflavonoids) reduces serum Lp(a) concentration (28) but it has not been established so far that soy fiber can reduce serum Lp(a).
Hypertriglyceridemia is common in PD patients (3, 29) . At baseline, mean serum triglyceride concentrations were 176 and 203 mg/dL in the soy and control groups respectively. Most patients had triglyceride levels in the normal range. The normality of serum triglyceride in these patients may be partly due to patients with high triglyceride levels taking gemfibrozil. In this study, soy consumption for 8 weeks did not alter serum triglyceride levels significantly. This finding is in agreement with those of some previous studies (16, 18, 22, 23, (36) (37) (38) but differs from findings of several other studies (17,19-21, 24,25) . To observe the effects of soy on serum triglyceride concentration, it is necessary to conduct such studies on hypertriglyceridemic patients. In the present study, mean serum triglyceride was within the normal range for the soy group; therefore, soy consumption was not expected to have any effect on serum triglyceride levels in these normotriglyceridemic patients. Serum total cholesterol, LDL-C, and apo B100 have been reported to be higher than normal in PD patients (29, 39) . At baseline, mean serum total cholesterol, LDL-C, and apo B100 were within the normal ranges for both the soy and the control groups. The normality of serum total cholesterol, LDL-C, and apo B100 in these patients may be due partly to patients with high concentrations of total cholesterol or LDL-C taking statins, including lovastatin.
In our study, soy consumption for 8 weeks had no significant effect on serum total cholesterol, LDL-C, or apo B100. In agreement with these findings, some previous studies have shown soy consumption causes no changes in serum total cholesterol (16, (36) (37) (38) , LDL-C (21,26, 36-38), or apo B100 (16, 18) . In contrast, some studies have indicated that soy reduces the level of serum total cholesterol (17) (18) (19) (20) (21) (22) (23) (24) (25) , LDL-C (16) (17) (18) (19) (22) (23) (24) (25) 38, (40) (41) (42) , and apo B100 (17, 19, 20, 23, 38, 40) .
These controversial findings may be due mainly to differences in baseline serum levels of total cholesterol, LDL-C, and apo B100. A meta-analysis on previous studies showed that soy reduces the levels of total cholesterol and LDL-C in hypercholesterolemic patients but not in normocholesterolemic individuals (25) . As mentioned earlier, the majority of patients in our study had serum total cholesterol, LDL-C, and apo B100 levels within the normal ranges; therefore, we cannot expect soy consumption to reduce serum total cholesterol, LDL-C, or apo B100 in these patients. In PD patients, the level of HDL-C is lower than the normal range (3, 29, 39) . In our study, soy consumption caused no significant change in serum HDL-C concentration. This finding is similar to those of most previous studies (16) (17) (18) 20, 21, 23, 24, 36, 37, 40) , whereas a few studies have indicated that soy increases serum HDL-C (22, 41) .
At baseline, mean serum apo AI was within the normal range (>110 mg/dL) for both groups. The serum concentration of apo AI was reduced significantly in the soy and the control groups. This result shows the observed decrease in the soy group is not due to soy consumption since it was also seen in the control group, which did not receive soy. The only probable explanation for this reduction is that serum lipids and apoproteins undergo some changes in normal range over time. This finding is in agreement with those of previous studies (16, 17, 20, 40) , confirming the ineffectiveness of soy consumption on serum apo AI concentration.
In the present study, 2 patients in the soy group were withdrawn because of noncompliance. We did not continue to follow these patients and so we cannot perform an intent-to-treat analysis; this is a weakness of our study.
In conclusion, this study indicates that soy consumption reduces serum Lp(a), which is a risk factor for CVD in peritoneal dialysis patients. Future studies should be done to clarify the mechanisms whereby soy consumption can reduce elevated serum Lp(a) concentration in peritoneal dialysis.
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